Press Release

Almirall: Lebrikizumab's 52-week late-breaking data will be presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress

- **The abstract entitled *Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)* will be presented at "Late-breaking News" session on Thursday, 8th September 2022**
- **Other six lebrikizumab and dermatology abstracts have been accepted by the EADV**

BARCELONA, Spain. September 1st, 2022 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that new data on the Phase 3 Trials (ADvocate1 and ADvocate2) of Lebrikizumab, an investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan (Italy) and online from September 7 to 10, 2022.

The abstract entitled *Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)* has been accepted as a late-breaking presentation at EADV to occur at the "Late-breaking News" session on Thursday, 8 September 2022.

Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Eli Lilly and Company has exclusive rights for development and commercialization of Lebrikizumab in the United States and the rest of the world outside Europe.

31st European Academy of Dermatology and Venereology Congress presentations and poster details:

A total of seven abstracts about lebrikizumab and dermatology data have been accepted by the EADV for their annual meeting.

Late Breaking Presentation: *Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2), Blauvelt et al*
Abstract number: 3456; Session code: D1T01.3
Thursday, September 8, 15:00h CEST (Late Breaking News Session)

Poster 1: *Lebrikizumab provides clinically meaningful responses in adults with moderate-to-severe atopic*

dermatitis in two phase 3 monotherapy studies. Thyssen J P et al.
(abstract ID: 418, poster ID: P0120)

Poster 2: *Lebrikizumab monotherapy improved itch in adults and adolescents with moderate to severe atopic dermatitis in two phase 3 trials. Yosipovitch G et al.*
(abstract ID: 765, poster ID: P0225)

Poster 3: *Monotherapy treatment with lebrikizumab in two phase 3 studies significantly reduced sleep-loss due to itching in adults and adolescents with moderate to severe atopic dermatitis. Ständer S et al.*
(abstract ID: #809, poster ID: P0227)

Poster 4: *Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase 3, randomized, double-blinded, placebo-controlled trials. Silverberg JI et al.*
(abstract ID: #231, poster ID: P0202)

Poster 5: *Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis: a phase 3, randomized, placebo-controlled trial (ADhere). Simpson E, et al.*
(abstract ID: 460, poster ID: P0213)

Poster 6: *Disease burden among patients with atopic dermatitis treated with systemic therapy for 4 to 12 months. Silverberg JI, et al.*
(abstract ID: 819, poster ID: P0230)

Poster availability date and time: From 7th September, 2022 (07.00 CEST) until 3 months post congress.

Location: MiCo Milano Convention Center, e-poster area and online

About Lebrikizumab

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity, slow disassociation rate and high potency to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. AD is an IL-13 dominant disease in which IL-13 drives skin barrier dysfunction, itch, skin thickening, and susceptibility to infection.[1-5]

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit almirall.com

Media contact Almirall:
Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors' Relations contact
Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Mar Ramírez
Phone: (+34) 659 61 41 73

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

[1] Moyle M, et al. *Exp Dermatol.* 2019;28(7):756-768.
[2] Ultsch M, et al. *J Mol Biol.* 2013;425(8):1330-1339.
[3] Zhu R, et al. *Pulm Pharmacol Ther*. 2017;46:88-98.
[4] Simpson EL, et al. *J Am Acad Dermatol*. 2018;78(5):863-871.e11.
[5] Okragly A, et al. *Comparison of the Affinity and in vitro Activity of Lebrikizumab, Tralokinumab, and Cendakimab*. Presented at the Inflammatory Skin Disease Summit, New York, November 3-6, 2021.